A Trojan horse for Parkinson's disease

Science Signaling

Volumn 3, Issue 116, 2010, Pages

  Hu, Yi ^a   Tong, Youren ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; RAS PROTEIN;

ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

HUMANS; MUTATION, MISSENSE; NEURONS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; ROTENONE;

EQUIDAE;

EID: 77953813288     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.3116pe13     Document Type: Review

References (30)

1. M. J. Farrer, Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306-318 (2006).
2. H. Melrose, Update on the functional biology of Lrrk2. Future Neurol. 3, 669-681 (2008).
3. Y. Tong, A. Pisani, G. Martella, M. Karouani, H. Yamaguchi, E. N. Pothos, J. Shen, R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 106, 14622-14627 (2009).
4. A. B. West, D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson, T. M. Dawson, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102, 16842-16847 (2005).
5. W. W. Smith, Z. Pei, H. B. Jiang, V. L. Dawson, T. M. Dawson, C. A. Ross, Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233 (2006).
6. C. J. Gloeckner, A. Schumacher, K. Boldt, M. Ueffing, The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 109, 959-968 (2009).
7. A. B. West, D. J. Moore, C. Choi, S. A. Andrabi, X. J. Li, D. Dikeman, S. Biskup, Z. Zhang, K. L. Lim, V. L. Dawson, T. M. Dawson, Parkinson's diseaseassociated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232 (2007).
8. B. Luzón-Toro, E. Rubio de la Torre, A. Delgado, J. Pérez-Tur, S. Hilfiker, Mechanistic insight into the dominant mode of the Parkinson's diseaseassociated G2019S LRRK2 mutation. Hum. Mol. Genet. 16, 2031-2039 (2007).
9. E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, A. Kaganovich, M. P. van der Brug, A. Beilina, J. Blackinton, K. J. Thomas, R. Ahmad, D. W. Miller, S. Kesavapany, A. Singleton, A. Lees, R. J. Harvey, K. Harvey, M. R. Cookson, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341 (2006).
10. R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, J. T. Greenamyre, Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306 (2000).
11. T. B. Sherer, R. Betarbet, A. K. Stout, S. Lund, M. Baptista, A. V. Panov, M. R. Cookson, J. T. Greenamyre, An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22, 7006-7015 (2002).
12. T. B. Sherer, R. Betarbet, C. M. Testa, B. B. Seo, J. R. Richardson, J. H. Kim, G. W. Miller, T. Yagi, A. Matsuno-Yagi, J. T. Greenamyre, Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23, 10756-10764 (2003).
13. D. L. Wang, B. S. Tang, G. H. Zhao, Q. Pan, K. Xia, R. Bodmer, Z. H. Zhang, Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener. 3, 3 (2008).
14. X. Lin, L. Parisiadou, X.-L. Gu, L. Wang, H. Shim, L. Sun, C. Xie, C.-X. Long, W.-J. Yang, J. Ding, Z. Z. Chen, P. E. Gallant, J.-H. Tao-Cheng, G. Rudow, J. C. Troncoso, Z. Liu, Z. Li, H. Cai, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein. Neuron 64, 807-827 (2009).
15. S. Saha, M. D. Guillily, A. Ferree, J. Lanceta, D. Chan, J. Ghosh, C. H. Hsu, L. Segal, K. Raghavan, K. Matsumoto, N. Hisamoto, T. Kuwahara, T. Iwatsubo, L. Moore, L. Goldstein, M. Cookson, B. Wolozin, LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210-9218 (2009).
16. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, R. L. Nussbaum, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 5276, 62045-2047 (1997).
17. J. Boudeau, D. Miranda-Saavedra, G. J. Barton, D. R. Alessi, Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452 (2006).
18. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
19. F. R. Papa, C. Zhang, K. Shokat, P. Walter, Bypassing a kinase activity with an ATP-competitive drug. Science 302, 1533-1537 (2003).
20. D. Han, A. G. Lerner, L. Vande Walle, J. P. Upton, W. H. Xu, A. Hagen, B. J. Backes, S. A. Oakes, F. R. Papa, IRE1α kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138, 562-575 (2009).
21. A. J. M. Cameron, C. Escribano, A. T. Saurin, B. Kostelecky, P. J. Parker, PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16, 624-630 (2009).
22. D. Salomon, A. Bonshtien, M. Mayrose, C. Zhang, K. M. Shokat, G. Sessa, Bypassing kinase activity of the tomato Pto resistance protein with small molecule ligands. J. Biol. Chem. 284, 15289-15298 (2009).
23. C. G. Zervas, N. H. Brown, Integrin adhesion: When is a kinase a kinase? Curr. Biol. 12, R350-R351 (2002).
24. Z. A. Knight, K. M. Shokat, Chemical genetics: Where genetics and pharmacology meet. Cell 128, 425-430 (2007).
25. N. D. Jorgensen, Y. Peng, C. C. Y. Ho, H. J. Rideout, D. Petrey, P. Liu, W. T. Dauer, The WD40 domain is required for LRRK2 neurotoxicity. PLoS ONE 4, e8463 (2009).
26. C. L. Klein, G. Rovelli, W. Springer, C. Schall, T. Gasser, P. J. Kahle, Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 111, 703-715 (2009).
27. S. Sen, P. J. Webber, A. B. West, Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 284, 36346-36356 (2009).
28. J. P. Deng, P. A. Lewis, E. Greggio, E. Sluch, A. Beilina, M. R. Cookson, Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U. S. A. 105, 1499-1504 (2008).
29. E. Greggio, I. Zambrano, A. Kaganovich, A. Beilina, J. M. Taymans, V. Daniëls, P. Lewis, S. Jain, J. Ding, A. Syed, K. J. Thomas, V. Baekelandt, M. R. Cookson, The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906-16914 (2008).
30. R. Gasper, S. Meyer, K. Gotthardt, M. Sirajuddin, A. Wittinghofer, It takes two to tango: Regulation of G proteins by dimerization. Nat. Rev. Mol. Cell Biol. 10, 423-429 (2009).